Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation

0301 basic medicine Binding Sites Ubiquitination Nuclear Proteins Protein Tyrosine Phosphatase, Non-Receptor Type 11 Polymorphism, Single Nucleotide 3. Good health Gene Expression Regulation, Neoplastic Pancreatic Neoplasms MicroRNAs 03 medical and health sciences DNA Repair Enzymes STAT1 Transcription Factor Case-Control Studies Proteolysis Humans RNA, Long Noncoding RNA Splicing Factors Extracellular Signal-Regulated MAP Kinases Pancreas Cell Proliferation Genome-Wide Association Study Signal Transduction
DOI: 10.1038/ng.3568 Publication Date: 2016-05-24T13:21:18Z
ABSTRACT
Genome-wide association studies have identified several loci associated with pancreatic cancer risk; however, the mechanisms by which genetic factors influence the development of sporadic pancreatic cancer remain largely unknown. Here, by using genome-wide association analysis and functional characterization, we identify a long intergenic noncoding RNA (lincRNA), LINC00673, as a potential tumor suppressor whose germline variation is associated with pancreatic cancer risk. LINC00673 is able to reinforce the interaction of PTPN11 with PRPF19, an E3 ubiquitin ligase, and promote PTPN11 degradation through ubiquitination, which causes diminished SRC-ERK oncogenic signaling and enhanced activation of the STAT1-dependent antitumor response. A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which diminishes the effect of LINC00673 in an allele-specific manner and thus confers susceptibility to tumorigenesis. These findings shed new light on the important role of LINC00673 in maintaining cell homeostasis and how its germline variation might confer susceptibility to pancreatic cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (65)
CITATIONS (224)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....